Search results
Results from the WOW.Com Content Network
On Tuesday, Danaher Corp (NYSE:DHR) reported third-quarter sales of $5.79 billion, up 3% year-over-year, beating the consensus of $5.59 billion. Guidance: Danaher reaffirms that in fiscal year ...
Danaher (DHR), with a 25% rise in shares in the past three months, benefits from strong demand, solid product offerings and synergies from buyouts. Shareholder-friendly policies add to its appeal.
In the latest trading session, Danaher (DHR) closed at $293.33, marking a -1.36% move from the previous day.
Danaher (DHR) outperforms its industry and the S&P 500 year to date on solid financial performances, buyout gains, solid product demand, shareholder-friendly policies and other factors.
Danaher (DHR) closed at $255.51 in the latest trading session, marking a -0.98% move from the prior day.
Danaher (DHR) closed the most recent trading day at $262.52, moving -0.5% from the previous trading session.
Danaher (DHR) delivered earnings and revenue surprises of 14.29% and 8.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Danaher's (DHR) Q3 results are expected to reflect a healthy demand for products in Life Sciences and Diagnostics segments. Also, Cytiva is anticipated to have aided core sales.